Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis

Authors

  • Zhuo Ma Pharmacy Department of Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.
  • Lifang Guo Pharmacy Department of Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.
  • Xiangli Cui Pharmacy Department of Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.
  • He Liu Pharmacy Department of Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.
  • Lihong Liu Pharmacy Department of Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.

DOI:

https://doi.org/10.18433/jpps30034

Abstract

Objectives: Endostar (recombinant human endostatin (rh-endostatin)), a 20-kDa proteolytic fragment of collagen XVIII, was approved for the treatment of non–small cell lung cancer (NSCLC). Recently, several studies have evaluated the efficacy of rh-endostatin combined with chemotherapy in the treatment of bone and soft tissue sarcomas. Here, we conducted a systematic review and meta-analysis to assess available evidence. Methods: Pubmed, Embase, Web of Sciences, the Cochrane Library and two Chinese literature databases (CNKI, WanFang) were systematically searched till May 20, 2018. Randomized controlled trials (RCTs) and cohort studies which compared the outcomes of rh-endostatin combined with chemotherapy versus chemotherapy alone for treating bone sarcomas or soft tissue sarcomas were included. The primary outcome was overall survival rate (OSR). Secondary outcomes included objectiveremissionrate(ORR), clinical benefit rate (CBR), disease control rate (DCR), distant metastasis rate (DMR) and adverse effects (AEs). The methodological quality of the included studies was evaluated. Data analysis was performed by Revman 5.3 software. Results: 9 studies comprising 839 patients were included. The pooled results indicated that, compared with chemotherapeutic agents alone, rh-endostatin combined group had a significant benefit in 1-year and 2-year OSR. However, there were no difference between 5-year OSR. OR, CBR and DMR were higher in rh-endostatin combined group. No significant difference was observed in the incidence of AEs. Conclusions: Rh-endostatin combined chemotherapeutic agents significantly improved clinical efficacy compared with chemotherapeutic agents alone in treating bone and soft tissue sarcomas. Moreover, combination of rh-endostatin with chemotherapy didn’t increase the incidence of AEs. But more high quality RCTs with  large  sample  size  should  be  done  in  the  future  to confirm the conclusion.

Downloads

Download data is not yet available.

Downloads

Published

2018-10-23

How to Cite

Ma, Z., Guo, L., Cui, X., Liu, H., & Liu, L. (2018). Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis. Journal of Pharmacy & Pharmaceutical Sciences, 21(1), 386–397. https://doi.org/10.18433/jpps30034

Issue

Vol. 21 (2018): Pages 305 - 515

Section

Systematic Review and Meta-Analysis

License

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.